Table 2.
3 HF-Specific Trials Involving SGLT2 Inhibitors
| DAPA HF25 | EMPEROR-Reduced26 | SOLOIST-WHF30 | |
|---|---|---|---|
| SGLT2 inhibitor | Dapagliflozin | Empagliflozin | Sotagliflozin |
| Median duration of follow-up, m | 18.2 | 16 | 9 |
| All | 4,744 | 3,730 | 1,222 |
| Asian | 1,076 (22.7) | 493 (13.2) | 15 (1.2) |
| Primary outcomea | HR: 0.74 (95% CI: 0.65-0.85); P < 0.001 | HR: 0.75 (95% CI: 0.65-0.86); P < 0.001 | HR: 0.67 (95% CI: 0.52-0.85); P < 0.001 |
| CV death | HR: 0.82 (95% CI: 0.69-0.98) | HR: 0.92 (95% CI: 0.75-1.12) | HR: 0.84 (95% CI: 0.58-1.22); P = 0.36 |
Values are n or n (%) unless otherwise indicated.
DAPA-HF = Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure; EMPEROR-Reduced = Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction; SOLOIST – WHF = Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure; other abbreviations as in Table 1.
a
Composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.